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ARTICLE

Differential engagement of Tim-1
during activation can positively or
negatively costimulate T cell expansion
and effector function

The Journal of Experimental Medicine
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It has been suggested that T cell immunoglobulin mucin (Tim)-1 expressed on T cells serves
to positively costimulate T cell responses. However, crosslinking of Tim-1 by its ligand Tim-4
resulted in either activation or inhibition of T cell responses, thus raising the issue of
whether Tim-1 can have a dual function as a costimulator. To resolve this issue, we tested a
series of monoclonal antibodies specific for Tim-1 and identified two antibodies that
showed opposite functional effects. One anti–Tim-1 antibody increased the frequency of
antigen-specific T cells, the production of the proinflammatory cytokines IFN-γ and IL-17,
and the severity of experimental autoimmune encephalomyelitis. In contrast, another anti–
Tim-1 antibody inhibited the generation of antigen-specific T cells, production of IFN-γ
and IL-17, and development of autoimmunity, and it caused a strong Th2 response. Both
antibodies bound to closely related epitopes in the IgV domain of the Tim-1 molecule, but
the activating antibody had an avidity for Tim-1 that was 17 times higher than the inhibitory antibody. Although both anti–Tim-1 antibodies induced CD3 capping, only the activating antibody caused strong cytoskeletal reorganization and motility. These data indicate
that Tim-1 regulates T cell responses and that Tim-1 engagement can alter T cell function
depending on the affinity/avidity with which it is engaged.
CORRESPONDENCE
Vijay K. Kuchroo:
vkuchroo@rics.bwh.harvard.edu
OR
Samia J. Khoury:
skhoury@rics.bwh.harvard.edu
Abbreviations used: AAD,
amino-actinomycin D; CHO,
Chinese hamster ovary; CNS,
central nervous system; EAE,
experimental autoimmune
encephalomyelitis; PLP, proteolipid protein; Tim, T cell
immunoglobulin mucin.
Published July 2, 2007

We recently identified a new gene family encoding the T cell immunoglobulin mucin (Tim)
proteins (1, 2). The Tim family consists of eight
genes in mouse (Tim-1–8) and three genes in
human (TIM-1, -3, and -4). Tim family members
are cell surface glycoproteins that share a common motif, including an IgV domain, a mucinlike domain, a transmembrane domain, and an
intracellular tail (1, 2). Tim family members are
differentially expressed on Th1 cells, Th2 cells,
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or DCs, and they are implicated in the regulation of asthma and autoimmunity (1).
TIM-1 was first identified as hepatitis A
virus cellular receptor 1 (3, 4), and later as a
kidney injury molecule 1 (5, 6). Interestingly,
hepatitis A virus infection is associated with
a reduced risk of developing asthma (7), and
in mouse models, Tim-1 has been genetically
linked to murine airway hypersensitivity (8).
Furthermore, polymorphic forms of TIM-1 in
humans have been associated with susceptibility to asthma, eczema, and rheumatoid arthritis
(9–13), suggesting that Tim-1 may play a role
in regulating immune responses. In addition to
1691

Published July 2, 2007

its expression on kidney cells, Tim-1 is also expressed on activated T cells. Upon CD4+ T cell polarization, it is expressed
at a higher level on Th2 cells than on Th1 cells (14, 15). Initial studies suggested that Tim-1 expressed on T cells is a
positive costimulatory molecule that results in enhancement
of T cell proliferation, cytokine production, and abrogation
of tolerance (14). Our laboratory has recently reported that
Tim-4, which is expressed on APCs, is a natural ligand for
Tim-1 (15). Interestingly, dependent on the dose, Tim-4
binding to Tim-1 has different effects on T cell proliferation.
A higher dose of Tim-4-Ig consistently led to an increase in
T cell proliferation upon TCR ligation, whereas a lower
concentration of Tim-4-Ig inhibited T cell proliferation (15).
Therefore, it was not clear whether Tim-1 is a positive or a
negative T cell costimulatory molecule. It is also possible,
however, that Tim-4 could induce these opposite effects by
engaging different receptors on the T cell surface. One possibility that would account for this apparent discrepancy is that
the Tim-1 molecule itself may be a positive regulator of
T cell responses, but that it may also act as an inhibitory molecule depending on how and when the molecule is engaged
during T cell activation. To date, however, all known costimulatory molecules have been categorized as positive costimulators (e.g., CD28 and ICOS) or negative costimulatory
molecules (e.g., CTLA-4 and PD-1), although some reports
suggested that CTLA4, which is an inhibitory molecule, can
up-regulate LFA-1 (16).
In this paper, we tested a series of anti–Tim-1 mAbs and
identified one antibody that positively costimulated T cell
responses and another that inhibited T cell responses. The
two antibodies also differentially regulated the expansion of
antigen-specific T cells, cytokine production, and development of autoimmunity in vivo. The two antibodies differed
17-fold in their binding avidity for Tim-1 and in the regulation of T cell cytoskeletal movement and TCR–CD3 capping,

RESULTS
Identification of anti–Tim-1 antibodies that either increase
or inhibit T cell proliferation
Tim-4 is a natural ligand for Tim-1 (15). Depending on the
dose, Tim-4-Ig can either increase or inhibit T cell proliferation upon TCR ligation, suggesting that Tim-1 may deliver both stimulatory and inhibitory costimulatory signals
into T cells (15). However, the inhibitory effects of Tim-4-Ig
might be caused by binding to a receptor other than Tim-1
on T cells. To understand the mechanism by which Tim-1
regulates T cell expansion and effector functions, we tested
a series of antibodies with binding specificity for Tim-1. It
was previously reported that Tim-1 engagement by an agonistic anti–Tim-1 antibody (clone 3B3) could costimulate
T cells along with TCR ligation (14). Indeed, when spleen
cells isolated from SJL mice immunized with the encephalitogenic peptide proteolipid protein (PLP)139-151 in CFA were
treated with antigen in vitro, addition of 3B3 anti–Tim-1
antibody to the cultures significantly increased T cell proliferation at all doses of antigens, compared with the treatment
with control rat IgG2a (rIgG2a; Fig. 1 A). Interestingly, in
contrast to 3B3, addition of another anti–Tim-1 antibody
(RMT1-10) reduced T cell proliferation in the cultures (Fig.
1 A). The data suggest that Tim-1 cross-linking with different antibodies can deliver either a positive or negative costimulatory signal in T cells, similar to what has been observed
with Tim-4-Ig (15).
We next determined the cytokine production in these
cultures after antigen-specific activation and addition of anti–
Tim-1 antibodies. As observed previously (17, 18), activation of PLP139-151-primed lymph node cells with the specific
antigen in the presence of control rIgG2a resulted in the

Figure 1. Opposite effects of the anti–Tim-1 antibodies 3B3 and
RMT1-10 on T cell responses. (A) Anti–Tim-1 antibody 3B3 enhances,
whereas RMT1-10 inhibits, antigen-specific T cell proliferation. Spleen cells
from PLP139-151-immunized SJL mice were cultured in vitro with different
concentrations of PLP139-151 plus 10 μg/ml RMT1-10, 3B3, or rIgG2a. Proliferation was measured after 48 h by 3[H]thymidine incorporation. The mean ±
SEM of three independent experiments are shown. *, P < 0.0001; **, P < 0.01,

relative to isotype control. (B) Treatment with RMT1-10 skews the
Th1/Th17 responses toward a Th2 response. Spleen cells from PLP139-151immunized SJL mice were cultured in vitro with 1 μg/ml PLP139-151 plus
10 μg/ml RMT1-10, 3B3, or rIgG2a. Supernatants were taken from the culture
at 48 h and assessed by cytokine ELISA for IFN-γ, IL-17, -4, and -10. Data
are representative of three independent experiments. Error bars represent
the SEM of triplicate measurements in the same experiment.
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production of the proinflammatory cytokines IFN-γ and
IL-17, with no detectable IL-4 or -10 in the cultures (Fig.
1 B). The addition of 3B3 increased the production of both
IFN-γ and IL-17 with no detectable production of IL-4 or -10
(Fig. 1 B). However, the addition of RMT1-10 to the cultures resulted in inhibition of IFN-γ and IL-17, but induced
the production of the Th2 cytokines IL-4 and -10 (Fig. 1 B).
Thus, the two anti–Tim-1 antibodies not only differed in their
ability to regulate T cell proliferation but also differentially induced cytokine production from the responding T cells.
Anti–Tim-1 antibodies 3B3 and RMT1-10 bind
to the same or closely related epitopes in the IgV
domain of the Tim-1 molecule
Because Tim-1 molecules contain both IgV and mucin domains in the extracellular region, it was possible that opposite
costimulatory functional effects on T cell responses by Tim-1
might be caused by engagement of different domains of
Tim-1 by the two antibodies. Therefore, 3B3 and RMT1-10
were tested in an ELISA assay for binding to full-length and
mucinless forms of Tim-1-Ig. Both 3B3, which was generated by immunizing rats with Tim-1 IgV-only fusion protein,
(14) and RMT1-10 bound to both full-length and mucinless forms of Tim-1 (Fig. 2 A), suggesting that both the
antibodies are specific for the IgV domain of Tim-1. The binding of both antibodies to the mucinless form was stronger

Figure 2. Characterization of 3B3 and RMT1-10 anti–Tim-1 antibodies. (A) ELISA plates were coated with goat anti–mouse IgG. Fulllength (Fl) or mucinless (Ml) Tim-1-Ig fusion proteins were used to coat
ELISA plates, and the binding of 3B3 and RMT1-10 to the fusion proteins
was determined. Tim-4-Ig was included as a negative control. Data are
representative of three independent experiments. Error bars represent the
SEM of triplicate measurements in the same experiment. (B) EL-4–Tim-1
transfectants were incubated with 0.5 μg/106 cells of unlabeled rIgG2a,
3B3, RMT1-10, or anti–Tim-3 antibody (clone 2C12) for 1 h on ice, and
0.5 μg/106 cells of either biotin-labeled RMT1-10 or PE-labeled 3B3 was
added into the reaction for another 30 min. The binding of 3B3 or RMT110 (followed by PE-conjugated streptavidin) was detected by flow cytometric analysis. The green lines show isotype control staining; the blue
lines show Tim-1 staining blocked with rIgG2a; the red lines show the
Tim-1 staining blocked with unlabeled 3B3, RMT1-10, or anti–Tim-3; the
yellow line shows the Tim-1 staining blocked with 5 μg/106 cells of unlabeled RMT1-10.
JEM VOL. 204, July 9, 2007

than the binding to full-length Tim-1. Neither antibody bound
to the negative control Tim-4-Ig fusion proteins.
To further determine whether 3B3 and RMT1-10 bind
to the same epitope in the Tim-1 IgV domain, we used one
antibody to stain Tim-1 transfectants and added in the other
antibody as a competitor to block this binding. As shown in
Fig. 2 B, when we used RMT1-10 to stain EL-4 cells transfected with Tim-1 (EL-4–Tim-1), addition of rIgG2a did not
block the binding, whereas the addition of unlabeled RMT1-10
strongly blocked the binding. The binding of RMT1-10 to
EL-4–Tim-1 cells was also strongly blocked by 3B3 anti–
Tim-1 antibody but not by anti–Tim-3 antibody. When
we used 3B3 to stain the EL-4–Tim-1 cells, addition of unlabeled 3B3 strongly inhibited the labeled 3B3 binding to the
Tim-1 transfectants, whereas addition of RMT1-10 in a 1:1
ratio weakly blocked the 3B3 binding (Fig. 2 B). However,
when higher amounts of RMT1-10 were used, we observed
an obvious inhibition of 3B3 binding to the EL-4–Tim-1
cells (e.g., 10:1 ratio, as shown in Fig. 2 B). These data suggest that both antibodies bind to the same or closely related
epitopes in the Tim-1 IgV domain.
Increase in early T cell dynamics induced by anti–Tim-1
antibody 3B3, but not by RMT1-10
Given that the two antibodies bind to the same or closely
related epitopes, but differed in their functional outcomes, we
hypothesize that the two antibodies might differ in the dynamics of early activation of T cells. Cytoskeletal changes, T cell
motility, and CD3 capping have been used as markers for the
early stages of T cell activation (19). Using live imaging of
T cells, we determined how the two antibodies affect the
kinetics of early CD4+ T cell responses.
Changes in cytoskeletal arrangements and motility offer a
readout for early stages in T cell activation, in addition to
membrane ruffling, and formation of lamellopodia resulting
from reorganization of TCR–CD3 and other costimulatory/
adhesion molecules (19). After addition of the anti–Tim-1 antibodies, there was no observable difference in the CD3 capping induced by the two antibodies. As shown in Fig. 3 A,
when treated with control rIgG2a, only a few cells showed
CD3 capping, and no more CD3 capping was observed 60 min
after the rIgG2a treatment, whereas addition of either 3B3 or
RMT1-10 within minutes induced rapid CD3 capping, as demonstrated by three-dimensional reconstruction of z-stack scanning of individual CD4+ T cells over time. Both 3B3 and
RMT1-10 treatment induced a similar percentage of CD4+ T
cells with CD3 capping during a 60-min observation (Fig. 3 A).
However, 3B3 treatment showed an increased percentage of motile T cells with persistent changes in morphology
and behavior. These effects peaked after 15 min, lasted for
30 min, and then began to drop. In contrast, the percentage of cells with body movement in the RMT1-10–treated
culture remained unchanged over 60 min (Fig. 3 A). Treatment with RMT1-10 antibody and control rIgG2a resulted
in only a very small percentage of motile CD4+ cells, and
the majority of the cells have a stationary behavior during
1693
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Figure 3. Effects of treatment with 3B3 or RMT1-10 on early T
cell responses. CD4+ T cells were stained with Alexa Fluor 488–conjugated
anti-CD3 on ice and treated with rIgG2a, 3B3, or RMT1-10 in a Live Imaging
Microincubator at 37°C and 5% CO2. The responses of labeled CD4+ T cells
were recorded for 1 h in 15-min intervals. CD3 capping at the 15-min time
point and time courses have been shown in A. The arrows represent cells

with CD3 capping. Pictures of the cell mobility were taken from 15 to 22
min, with 104-s intervals, and are shown in B. The arrows represent the cells
with active body movement. The time course of the cell mobility has been
shown in B. The video of T cell mobility from 15 to 22 min is shown Video 1.
Green, CD3; red (A) and purple (B), differential interface contrast. Video 1 is
available at http://www.jem.org/cgi/content/full/jem.20062498/DC1.

the recorded time points. Most strikingly, treatment with 3B3
caused persistent changes in T cell morphology and motility,
whereas both rIgG2a and RMT1-10 treatments induced
very little motility, and no major change in morphology
(Video 1, available at http://www.jem.org/cgi/content/full/
jem.20062498/DC1).
This suggested that the Tim-1 molecule induced important changes in T cell activation. Both appear to engage receptors in the membrane that induced a robust CD3 capping;
strikingly, only 3B3 antibody resulted in a subsequent robust
motility and cytoskeletal rearrangements (20).

After capture of 3B3 or RMT1-10 on the surface of a
goat anti–rat IgG Fc biosensor chip, a concentration series of
Tim-1-Ig was injected over the antibodies and used to generate high-resolution kinetic data (Fig. 4 A). Association (Ka)
and dissociation (Kd) rate constants for each antibody were
derived from a global fit of Tim-1-Ig binding data using a
bivalent analyte model. Both 3B3 and RMT1-10 had rapid
association rates with Tim-1, mean Ka = 3.8 × 106 and 3.2 ×
106 M−1s−1, respectively, but significantly different rates of
antibody–antigen complex dissociation, mean Kd = 1.05 ×
10−3 and 1.02 × 10−2 s−1, respectively (P = 0.007). The
resulting difference in binding avidities (KD) was primarily
dependent on the significantly faster off-rate of Tim-1 from
RMT1-10 (Fig. 4 B). The mean avidity of 3B3 for Tim-1 is
17-fold higher than that of RMT1-10 (mean KD = 0.294 vs.
5.102 nM, respectively). Thus, the stronger T cell activation
is likely a consequence of a higher-avidity interaction of 3B3
and Tim-1 molecules. This might result in a more stable
Tim-1 complex, which associates with the TCR–CD3 complex to form large supramolecular activation clusters (19).
Furthermore, the biacore analysis confirms that 3B3 and
RMT1-10 bind closely related epitopes on Tim-1 (Fig. 4 C).
Compared with control rIgG2a, preincubation of Tim-1 with
3B3 almost completely eliminated the ability of 3B3 that was
captured on the surface of the biosensor chip to bind Tim-1.
Interestingly, preincubation of Tim-1 with RMT1-10 partially

3B3 has a 17-fold higher binding avidity than RMT1-10
anti–Tim-1 antibody
Because the two antibodies bound to the same or closely
related epitopes in the Tim-1 IgV domain, the divergent effects
of 3B3 and RMT1-10 on early T cell activation events and
proliferation could not be explained by their binding specificity of the Tim-1 molecule. However, because 3B3 strongly
blocked the binding of RMT1-10 to EL-4–Tim-1 cells,
whereas RMT1-10 only inhibited 3B3 binding to the cells
only at a very high concentration (Fig. 2 B), 3B3 might have
a higher Tim-1 binding avidity than RMT1-10. Therefore,
biacore analysis of 3B3 and RMT1-10 binding to Tim-1
molecules was undertaken to determine their binding kinetics
and avidities.
1694
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Figure 4. Biacore analysis of 3B3 and RMT1-10 interactions
with Tim-1 molecules. (A) 3B3 and RMT1-10 were captured on the
surface of a biosensor chip, and a concentration series of Tim-1-Ig was
used to generate high-resolution kinetic data. Tim-1 association and
dissociation data were acquired and rate constants (Ka and Kd) were
generated from a global fit of the experimental binding data using a
bivalent analyte model (mean χ2 = 0.329 for 3B3 and 0.471 for RMT1-10).
Sensogram data are representative of five independent experiments.
(B) Association/dissociation rate plot showing resolution of binding affinities for each antibody. Isoaffinity diagonals indicate constant affinity
values that increase from bottom left to top right. Mean affinities

(KD = Kd/Ka) for 3B3 and RMT1-10 are indicated within the plot. Data
are the mean ± the SEM of five independent experiments. (C) Antibody
blocking was used to examine the 3B3 and RMT1-10 epitopes on Tim-1.
Tim-1-Ig was preincubated with anti–Tim-1 antibodies and observed for
binding to 3B3 captured on the surface of a biosensor chip. RMT1-10
significantly reduced, but did not eliminate, Tim-1 binding to 3B3. Data
are representative of three independent experiments. The RUs of immobilized anti–Tim-1 for the experiment in A were 137–141 for 3B3 and
108–113 for RMT1-10. In the experiment shown in C, the RUs were
360–365. In all cases, the “DeltaRUs” in the Tim-1 antibody immobilized
on the chips was <5%.

inhibited the binding of Tim-1 by captured 3B3, further corroborating that the opposite effects of 3B3 and RMT1-10
antibodies do not have different binding specificity, but differential binding avidity for the Tim-1 molecule.

administration of activating anti–Tim-1 antibody results in a
hyperproliferation of T cells in vivo, such that they continue
to proliferate ex vivo, even in the absence of further activation. Cytokine ELISA showed that even without antigenic
restimulation, spleen cells from 3B3-treated mice secreted
large quantities of IFN-γ, IL-17, -2, -6, and TNF-α (Fig. 5 A
and not depicted), which correlated with the higher level of
basal proliferation observed in these cultures. Spleen cells
from mice treated with rIgG or PBS produced only little of
these cytokines in the absence of antigen. However, spleen
cells from control-treated mice showed a dose-dependent increase in the production of these cytokines upon in vitro
activation with PLP139-151. Spleen cells from 3B3-treated
mice showed a similar dose-dependent increase in cytokine
production, but the amounts of cytokines produced were
two to four times higher than those from control-treated
mice. The production of IL-4 and -10 was very low and
comparable between 3B3-treated and control groups (Fig. 5 A
and not depicted). These data indicate that treatment with
activating high-avidity anti–Tim-1 antibody enhances proinflammatory Th1 and Th17 responses.
We next analyzed the frequency of PLP139-151-specific
CD4+ T cells using MHC class II/IAs tetramers specific for
PLP139-151 peptide (17, 28). In cultures derived from 3B3treated mice immunized with PLP139-151, there were approximately twofold more PLP139-151/IAs tetramer-positive CD4+
T cells than in cultures from control mice (Fig. 5 B; 1.76 vs.
0.95%, P = 0.00056). Furthermore, the frequency of IL-17–
producing PLP139-151/IAs-reactive CD4+ T cells was almost
fourfold higher in 3B3-treated mice than that in control mice
(Fig. 5 C; 8.01 vs. 2.24%, P = 0.0016). 3B3 treatment also increased the frequency of IFN-γ–producing PLP139-151-specific
CD4+ T cells, although the increase in IFN-γ–producing
cells was not as high as observed for IL-17–producing cells.
These data demonstrate that administration of high-avidity

Administration of activating anti–Tim-1 antibody 3B3
expands autopathogenic Th1 and Th17 cells
Tim-1 regulates the early activation of T cells. Depending on
the avidity of its cross-linking, it can either enhance or inhibit T cell proliferation and regulate production of cytokines
(Fig. 1). These traits are similar to those of agonistic/antagonistic TCR peptide ligands (also known as altered peptide
ligands) (21). Because the two antibodies have divergent
effects on T cell responses in vitro, we next examined their
effects in vivo on T cell responses and the development of
experimental autoimmune encephalomyelitis (EAE), which
is an animal model of autoimmune inflammatory disease in
the central nervous system (CNS) that serves as an animal
model for multiple sclerosis (22). EAE is mediated by myelinreactive CD4+ T cells, and many studies suggest that both
Th1 and Th17 cells are crucial for its development (18,
23–25), whereas Th2 cells that produce IL-4 and -10 have been
shown to inhibit and reverse EAE (26, 27). Our in vitro
results predict that the activating anti–Tim-1 antibody 3B3
would enhance pathogenic T cell responses and autoimmunity,
whereas RMT1-10 would inhibit them.
To determine the effect of 3B3 on the development of
antigen-specific T cell responses, spleen cells from PLP139-151immunized SJL mice treated with 3B3 or control reagents
were tested for T cell proliferation and cytokine production
ex vivo. As shown in Fig. 5 A, spleen cells from 3B3-treated
mice had 3–5 times the basal proliferation in the absence of
any exogenous antigen. These cells also showed increased
proliferation upon addition of low doses of antigen, compared with those from control mice. These data suggest that
JEM VOL. 204, July 9, 2007
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Figure 5. Treatment with 3B3 enhances PLP139-151-specific Th1
and Th17 responses. (A) Spleen cells from immunized SJL mice treated
in vivo with 3B3, or with rIgG or PBS as control, were cultured in vitro for
48 h with PLP139-151 restimulation. Proliferation was measured in triplicate
wells after 48 h by 3[H]thymidine incorporation. Supernatants were taken
at 48 h from the culture and assessed by cytokine ELISA for IL-2, IFN-γ,
IL-17, -6, -4, and -10. Splenocytes from individual mice (n = 4) were
analyzed separately, and mean data for all mice are shown. (B) Lymphocytes from spleen and lymph nodes of immunized SJL mice treated with
3B3 or rIgG were cultured in vitro for 5 d with PLP139-151 restimulation.

Live cells were obtained by Ficoll-Hypaque density gradient centrifugation
and used for triple color staining with PE-conjugated IAs tetramer, APC–
anti-CD4, and 7-AAD. The PLP139-151/IAs tetramer-positive cells were determined in the live CD4+ cell population (CD4+7-AAD−). Cells were also
reactivated with PMA and ionomycin for 4 h and used for four-color
staining with APC-conjugated IAs tetramer, FITC–anti-CD4, 7-AAD, and
PE-cytokine. (C) The number of cytokine-producing cells was determined
in the PLP139-151/IAs tetramer-positive CD4+ cell population. Data are representative of three independent experiments.

anti–Tim-1 antibody promotes the expansion of antigenspecific proinflammatory Th1/Th17 cells, as well as production of proinflammatory cytokines from these cells. These
results would predict that increased proinflammatory cells and
cytokines that were induced by activating anti–Tim-1 3B3
antibody would promote autoimmunity.

treated mice died 3–4 d after the onset of disease (Table I).
Histological examination of brains and spinal cords did not
show striking differences in the numbers of inflammatory/
demyelinating lesions in 3B3 versus control-treated mice
(Table I). However, inflammatory lesions were observed as
early as day 8 in the 3B3 antibody-treated mice, but not in
the rIgG-treated group. Furthermore, large numbers of
neutrophils were regularly identified in the lesions of 3B3treated mice, but not in control mice (unpublished data).
There was also a trend toward larger areas of demyelination in the 3B3-treated mice, suggesting that treatment with
3B3 resulted in more leukocyte infiltration and more tissue
damage in the CNS that correlated with severe, unremitting
disease in the treated mice. Collectively, these results suggest that cross-linking of Tim-1 by an activating anti–Tim-1

Treatment with activating anti–Tim-1 antibody 3B3
enhances the severity of EAE
To test the potential effect of the activating anti–Tim-1 antibody on the regulation of EAE, SJL mice were immunized
with the encephalitogenic PLP139-151 peptide, and treated with
3B3 or control reagents. Whereas the control groups (rIgG
and PBS) showed a typical EAE course, treatment with 3B3
dramatically altered the course of EAE (Fig. 6). 80% of 3B3-

Table I. Clinical and histological EAE in anti–Tim-1 antibody 3B3-treated SJL mice
Histopathology
(Number of
inflammatory
lesions)

Clinical disease

Treatment
PBS
rIgG
3B3
a,bP

Incidence
(sick/total)
8/8
8/8
10/10

Mean day of onset
(mean ± SEM)
9.75 ± 0.46
10.25 ± 0.89
9.25 ± 0.46

Mean maximum score
(mean ± SEM)
3.25 ± 0.60
3.50 ± 0.89
4.75 ± 0.46a

Mortality
(death/total)
0/8
1/8
8/10b

Meninges
78 ± 29
72 ± 30
68 ± 42

Parenchyma
(mean ± SEM)
110 ± 17
110 ± 40
120 ± 33

Total
188 ± 18
182 ± 56
188 ± 61

< 0.05, 3B3-treated group compared with rIgG- or PBS-treated group.
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T cells was about twofold lower in RMT1-10–treated mice
than in control mice (Fig. 7 C; 2.68 vs. 5.18%, P = 0.0019).
The frequency of IFN-γ–producing PLP139-151/IAs-reactive
CD4+ T cells was slightly decreased in RMT1-10–treated
mice. These data suggest that administration of the lowavidity anti–Tim-1 antibody RMT1-10 inhibits expansion
and cytokine production of proinflammatory T cells, especially Th17 cells.

Figure 6. Administration of 3B3 anti–Tim-1 antibody enhances
EAE severity. 8–12-wk-old female SJL mice were actively immunized
with PLP139-151 emulsified in CFA, and treated with 3B3, rIgG, or PBS every
other day from day 0 to 8. Mice were evaluated daily for the signs of EAE.

antibody in vivo during T cell activation not only enhances
proinflammatory Th1 and Th17 responses, but also has functional consequences in that it dramatically enhanced the progression and severity of EAE.
Inhibitory anti–Tim-1 antibody RMT1-10 decreases antigenspecific CD4+ T cell expansion and production of IFN-𝛄
and IL-17 by these cells
When SJL mice were immunized with PLP139-151 and treated
with the anti–Tim-1 antibody RMT1-10, their spleen cells
had a lower basal proliferation in the absence of antigen and
decreased proliferation in the presence of antigen, compared
with the control (Fig. 7 A). PLP139-151/IAs tetramer staining
demonstrated that the frequency of PLP139-151-specific CD4+
T cells decreased nearly twofold in cells derived from RMT110–treated mice compared with those from the control mice
(Fig. 7 B; 0.43 vs. 0.91%, P = 0.0018). Furthermore, the
frequency of IL-17–producing PLP139-151/IAs-reactive CD4+

Figure 7. Treatment with RMT1-10 anti–Tim-1 antibody inhibits
PLP139-151-specific T cell responses. (A) Spleen cells from immunized
SJL mice treated in vivo with RMT1-10 or rIgG were cultured in vitro for
48 h with PLP139-151 restimulation. Proliferation was measured in triplicate
wells after 48 h by 3[H]thymidine incorporation. (B and C) Lymphocytes
from spleen and lymph nodes of immunized SJL mice were cultured for
JEM VOL. 204, July 9, 2007

Administration of RMT1-10 inhibitory anti–Tim-1 antibody
inhibits the development of EAE
Next, we determined whether the reduced frequency of Th1
and Th17 cells upon RMT1-10 treatment also translated into
an attenuation of EAE. Indeed, in contrast to treatment with
3B3, administration of RMT1-10 inhibited the development
of EAE (Fig. 8). Only 30% of RMT1-10–treated mice developed EAE, whereas all of the rIgG-treated mice developed
severe EAE. Furthermore, RMT1-10 treatment not only
dramatically decreased the severity of EAE but also delayed
the disease onset (Table II). Histological examination of brain
and spinal cords demonstrated a significant decrease in the
number of inflammatory lesions in the meninges and parenchyma in RMT1-10–treated mice compared with control
animals (Table II). These data suggest that the low-avidity
anti–Tim-1 antibody RMT1-10 inhibits EAE when administrated in vivo during the induction phase, which is opposite
to the effect of the activating high-avidity anti–Tim-1 antibody 3B3.
DISCUSSION
T cell activation is a tightly regulated event involving complex receptor–ligand interaction, ultimately leading to downstream signaling events. Optimal T cell activation requires at
least two signals, antigen recognition and costimulation (29–31).
The TCR–CD3 complex, which recognizes antigens presented by MHC molecules, is critical in maintaining the

5 d with PLP139-151 restimulation. Live cells were then obtained by FicollHypaque density gradient centrifugation and used for determining the
frequency of PLP139-151/IAs tetramer-positive CD4+ cells and cytokine production from these cells as described in Fig. 5 (B and C). Data are representative of three independent experiments.
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Figure 8. Administration of RMT1-10 anti–Tim-1 antibody inhibits
EAE. Female SJL mice were actively immunized with PLP139-151 emulsified
in CFA and treated with RMT1-10 or rIgG every other day from day 0 to 10.
Mice were evaluated daily for the signs of EAE.

specificity of T cell responses. Signal two, or costimulation, is
an antigen-independent signal required for sustained T cell
activation, proliferation, and survival. Although several costimulatory molecules have been identified that can either
enhance (e.g., CD28 and ICOS) or inhibit (e.g., CTLA4 and
PD-1) T cell responses in terms of T cell activation, none of
these molecules has been found to both activate and inhibit
T cell proliferation/cytokine responses. With the specific
anti–Tim-1 antibodies described here, we provide evidence
that engagement of Tim-1 can both activate and inhibit
T cell responses. We have shown that two mAbs that are
both specific for the IgV domain of Tim-1 have different
effects on T cell activation and subsequent responses mainly
because of the difference of their binding avidity, but not
binding specificity. Because both anti–Tim-1 antibodies were
specific for Tim-1 and did not cross react with other Tim
family members, this places Tim-1 in a unique position in the
category of T cell costimulatory molecules. Tim-1 may represent a third category of costimulatory molecules that can
deliver both positive and negative costimulatory signals depending on how it is engaged during T cell activation.
Published
July anti–Tim-1
2, 2007
The
antibodies 3B3 and RMT1-10 had opposite effects on T cell responses and the development of
an autoimmune disease. The opposite effects of the two antibodies apparently are not caused by their binding specificity

because both antibodies bound to closely related epitopes in
the Tim-1 IgV domain. However, based on the biacore
analysis, it was evident that the activating anti–Tim-1 antibody had an avidity that was 17 times higher than the inhibitory antibody RMT1-10. Because Tim-1 appears to be
a costimulatory signaling molecule (14, 32), higher-avidity
antibodies like 3B3 could enhance T cell activation by forming a stable Tim-1 complex and bringing Tim-1 into the
TCR–CD3 complex, and they also help form large supramolecular activation clusters for full T cell activation (19). On
the other hand, low-avidity antibodies like RMT1-10 have
a significantly faster off-rate and may not support the formation of stable Tim-1–TCR–CD3 complexes. Akin to partial
agonist/antagonist TCR ligands, low-avidity engagement of
Tim-1 by RMT1-10 might only lead to partial T cell activation. Many of the partial agonist/antagonist TCR ligands
have been shown to induce a partial signal into T cells, induce
Th2 responses in vivo, and prevent development of autoimmune diseases (21, 33, 34). Strikingly, in agreement with this,
treatment with RMT1-10, indeed, induced a Th2 response,
even under proinflammatory immunization conditions. Our
data clearly show that the 3B3 antibody induced a stronger
cytoskeletal activation and motility, although the percentage
of CD4+ T cells forming CD3 caps is not different between
the two antibody treatments (Fig. 3 and Video 1). Furthermore, we found that monovalent Fab′ fragments of 3B3, like
bivalent 3B3, enhanced Th1 and Th17 responses, whereas
Fab′ fragments of RMT1-10, such as bivalent RMT1-10,
decreased Th1 and Th17 responses and increased Th2 responses. However, the Fab′ fragments of both anti–Tim-1
antibodies did not change Th cell proliferation significantly
upon antigen restimulation (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20062498/DC1). These data
suggest that the mere affinity (binding strength of Tim-1
and antibody) of Tim-1 engagement might contribute to
the quality of the resulting T cell response. Also, because,
similar to the intact antibodies, the Fab′ fragments of 3B3
and RMT1-10 induced skewing of the T cell response, it is
unlikely that the results observed with the intact antibodies
were caused by differences in the binding of Tim-1 (monovalent vs. bivalent) (35), but instead the stability of the Tim-1–
antibody complex and the number of Tim-1 molecules engaged at a given time point might account for the differential

Table II. Clinical and histological EAE in anti–Tim-1 antibody RMT1-10-treated SJL mice
Histopathology
(Number of
inflammatory
lesions)

Clinical disease

Treatment
rIgG
RMT1-10

Incidence
(sick/total)
6/6
3/10

Mean day of onset
(mean ± SEM)
10.75 ± 1.16
14.00 ± 3.46a

Mean maximum score
(mean ± SEM)
3.38 ± 0.92
2.00 ± 1.00b

Mortality
(death/total)
1/6
0/10

Meninges
97 ± 33
35 ± 26c

Parenchyma
(mean ± SEM)
87 ± 18
27 ± 19d

Total
185 ± 33
63 ± 35e

a,bRepresenting
c,d,eP

the mice that showed clinical signs of EAE (3 out of 10 mice).
< 0.05, RMT1-10–treated group compared with rIgG- or PBS-treated group.
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T cell responses. However, the differences in the effect of
the two antibodies on proliferation appears to be significantly
affected when intact rather than when the Fab′ fragment was
used in T cell proliferation assays, suggesting that the two
T cell responses (proliferation vs. cytokine production) can
be separated, depending on whether monovalent or bivalent
antibodies are used.
Our data cannot exclude the possibility that interaction
of Tim-1 with its ligand is an inhibitory interaction and that
antibodies like 3B3 and RMT1-10 are differentially blocking this inhibitory interaction. Tim-1 has been shown to
bind to itself by a homophilic interaction (36), and also to
Tim-4, which is preferentially expressed on the antigenpresenting cells (15). Indeed, the Tim-1–Tim-4 interaction
can be strongly blocked by high-avidity 3B3 antibody,
whereas low-avidity antibody RMT1-10 showed a weak
inhibition only at a very high dose (unpublished data).
Whether the blockade of Tim-1–Tim-4 or Tim-1–Tim-1
interaction by anti–Tim-1 antibodies (3B3 or RMT1-10)
contributes to the differential T cell responses observed here
need to be further investigated. Furthermore, biochemical
differences in the signaling mediated by the affinity/avidity
of the two antibodies will further help discern the mechanism by which the two anti–Tim-1 antibodies mediate such
opposite effects.
It has been reported that administration of 3B3 prevented
development of respiratory tolerance and led to the development of airway hyperreactivity (14). Using this activating
high-avidity anti–Tim-1 antibody, we showed that 3B3
in vivo strongly enhanced pathogenic Th1/Th17 responses,
leukocyte infiltration, and tissue injury in the CNS, and increased disease severity of EAE. Both Th1 and Th17 T cell
subsets have been shown to be critical for the tissue inflammation and pathogenesis of EAE (18, 23–25, 37). Using
PLP139-151/IAs tetramers, we further analyzed the expression
of cytokines in tetramer-positive cells. In 3B3-treated mice,
the frequency of IFN-γ–producing PLP139-151-reactive Th
cells was only slightly increased, indicating that the effect of
3B3 treatment on increase of IFN-γ production might
Published
2007
mainlyJuly
be2,caused
by expansion of the responding T cells.
There was an even bigger expansion in Th17 cells (nearly
fourfold increase) in 3B3-treated mice. Besides increasing
IFN-γ and IL-17, 3B3 enhanced IL-6 production from the
responding T cells as well. Because we and others have recently shown that IL-6 is a key cytokine that, together with
TGF-β, promotes differentiation of Th17 cells (18, 38), increased generation of Th17 cells by activating anti–Tim-1
antibody may be partly caused by the induction of IL-6 by
3B3 in T cells. Together with TGF-β, this induction of IL-6
might be responsible for the generation of Th17 cells in
3B3-treated mice. A previous report suggested that 3B3
antibody could enhance both production of IFN-γ and Th2
cytokines (14); however, we could not detect IL-4 or -10 in
our study. This is likely caused by strain differences (SJL vs.
BALB/c) in that in the previous study the authors used a
Th2-prone strain, BALB/c, whereas most of our studies are
JEM VOL. 204, July 9, 2007

undertaken with the SJL mice. The low-avidity anti–Tim-1
antibody RMT1-10 inhibited T cell expansion and proinflammatory cytokine production and promoted the generation of Th2 responses. This reduction in T cell proliferation
and change in cytokine profile was paralleled by the inhibition of EAE in the RMT1-10–treated mice. The mechanism
by which this anti–Tim-1 antibody inhibited EAE could be
caused by both reduction of encephalitogenic Th1/Th17 responses and induction of Th2 responses. Both Th2 cytokines
IL-4 and -10 have previously been shown to suppress EAE,
and an increase in Th2 cytokines has been shown to accumulate in the CNS during recovery and to precede remission (25). Of the two cytokines, IL-10 has been shown to
have more profound effect in regulating EAE (27). IL-4 has
also recently been shown to potently inhibit the generation
of Th17 cells (24, 37).
A subset of CD4+ cells called CD4+CD25+ regulatory
T cells (T reg cells) that express Forkhead box P3 (Foxp3)
can control autoimmune responses (39, 40). T reg cells have
recently been shown to confer significant protection from
the development of EAE (41), but also traffic to the target
tissue and impact on the local milieu (42). We reported that
there is a dichotomy in Th17 and FoxP3+ T reg cells (18).
Whether increased severity of EAE in 3B3-treated mice or
inhibition of EAE in RMT1-10–treated mice is also caused
by alteration in the number and/or function of FoxP3+ T reg
cells is not clear. Our preliminary data suggest that there is no
decrease in the number of T reg cells in 3B3-treated mice or
increase of T reg cells in RMT1-10–treated mice. However,
whether treatment with 3B3 or RMT1-10 antibody alters
the generation or function of antigen-specific T reg cells will
need to be further investigated.
In conclusion, we found that Tim-1 plays an important
role in the regulation of T cell responses and the development of autoimmune disease. The high-avidity anti–Tim-1
antibody enhances the severity of EAE because of increasing
autopathogenic Th1 and Th17 responses, whereas the lowavidity antibody inhibits autopathogenic Th1 and Th17 responses and EAE and induces a strong Th2 response. The data
suggest that Tim-1 may represent a new category of T cell
costimulators that can positively and negatively costimulate
T cell responses depending on how they are engaged during
T cell activation, similar to the TCR ligands that can change
functional outcomes depending on avidity with which TCR
is engaged. Manipulating the Tim-1 pathway may have a
therapeutic potential for many different diseases. Although
antibodies with characteristics of 3B3 would be useful as vaccine adjuvants and in the treatment of cancers and infectious
diseases, antibodies like RMT1-10 would be useful in treating autoimmune diseases and transplant rejections.
MATERIALS AND METHODS
Mice and antigen. SJL mice were purchased from The Jackson Laboratory.
The mice were maintained and all animal experiments were done according to the animal protocol guidelines of Harvard Medical School. PLP139-151
(HSLGKWLGHPDKF) was synthesized by Quality Controlled Biochemicals and was >90% pure, as determined by HPLC.
1699

Published July 2, 2007

Generation of Tim transfectants and anti–Tim-1 mAbs. Mouse Tim-1
cDNA was cloned into the pDisplay vector (Invitrogen) and transfected into
Chinese hamster ovary (CHO) and EL-4 cells using a previously described
method (43). Anti–Tim-1 mAb 3B3 (rat IgG2a, κ) was generated using mucinless Tim-1-Ig, which contains the IgV domain only, as immunogen (14).
Anti–mouse Tim-1 mAb RMT1-10 (rat IgG2a, κ) was generated by immunizing SD rats with full-length Tim-1-Ig that contained both IgV and mucin
domains of Tim-1. Lymph node cells were then fused with P3U1 myeloma
cells and cloned. The hybridomas were screened for binding to mouse Tim1–transfected CHO cells, but not the parental CHO cells. The specificity
of the anti–Tim-1 antibodies were further determined by staining EL-4 and
CHO cells transfected with different Tim family members.
Induction and clinical evaluation of EAE. 8–12-wk-old female SJL
mice were immunized subcutaneously in the flanks with an emulsion containing PLP139-151 (80 μg/mouse) and 4 mg/ml Mycobacterium tuberculosis
H37Ra extract (DIFCO) in CFA. Pertussis toxin (100 ng/mouse; List
Biological Laboratories) was administered intravenously on days 0 and 2.
Mice were intraperitoneally injected with 100 μg 3B3, RMT1-10, rIgG,
or PBS every other day from day 0 to 8. Mice were monitored and assigned grades for clinical signs of EAE using the following scoring system:
0, healthy; 1, limp tail; 2, impaired righting reflex or waddled gait; 3,
hind limb paralysis; 4, total limb paralysis; 5, moribund or death. At different time points, brains and spinal cords were removed and fixed in 10%
phosphate-buffered formalin and examined histologically for numbers of
inflammatory foci and demyelination.
Proliferation assays and ELISA. Female SJL mice were immunized with
PLP139-151/CFA and treated with anti–Tim-1 or control antibodies as described
in the previous section. Mice were killed at the time of disease onset (on day
10 for 3B3 treatment and on day 14 for RMT1-10 treatment) and spleens were
removed. Spleen cells were isolated and plated in round-bottomed 96-well
plates (BD Biosciences) in culture medium with various concentrations of
PLP139-151. After 48 h, culture supernatants were removed for cytokine ELISA
and cytokine production was measured by quantitative capture ELISA, as previously described (43). Plates were pulsed for 16 h with 1 μCi [3H]thymidine
per well. Proliferation was measured as counts per minute by using a Wallac
Liquid Scintillation Counter (Perkin Elmer).
IAs Tetramer staining and intracellular staining. IAs tetramers for
PLP139-151 and TMEV70-86 were generated as previously described (17, 28).
TMEV tetramers were used as negative controls. Lymphocytes from spleen
and lymph nodes of PLP139-151-immunized SJL mice treated with different
antibody were cultured with 20 μg/ml of antigen for 5 d. Cells were purified by Ficoll-Hypaque density gradient centrifugation. After washing, cells
were incubated with the tetramers (30 μg/ml) for 3 h at 37°C, followed by
staining with anti–CD4-APC (clone RM4.5) and 7-amino-actinomycin D
(7-AAD; BD Biosciences). Cells were acquired by using the FACSort flow
cytometer (Becton Dickinson), and tetramer-positive cells were determined
within the CD4+ population after gating the viable cells (7-AAD−). FACS
data were analyzed with the CELLQUEST (Becton Dickinson) and FlowJo
(Tree Star) programs. To determine the frequency of cytokine-producing
cells, Ficoll-purified cells were reactivated with 20 ng/ml PMA (SigmaAldrich) and ionomycin (300 ng/ml; Sigma-Aldrich) and 2 mM monensin
(GolgiStop; BD Biosciences) for 4 h at 37°C. After staining with tetramer,
anti–CD4, and 7-AAD, the cells were fixed, permeabilized, and stained with
cytokine antibody as recommended by the manufacturer (BD Biosciences).
The frequencies of cytokine-producing cells were analyzed by gating on
tetramer+CD4+7-AAD− populations.
Anti–Tim-1 binding ELISA. ELISA plates were coated with 10 μg/ml
of AffiniPure goat anti–mouse IgG (Jackson ImmunoResearch Laboratories,
Inc.). After overnight incubation at 4°C and washing, the plates were then
coated with 50 nM of full-length or mucinless mouse Tim-1-Ig or Tim-4-Ig
fusion protein. After blocking, different concentrations of anti–Tim-1 were
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added, followed by peroxidase-conjugated AffiniPure goat anti–rat IgG secondary antibody (Jackson ImmunoResearch Laboratories). Assays were developed with TMB Microwell Peroxidase Substrate (Kierkegaard and Perry
Laboratories) and read at 450 nm using a Benchmark microplate reader
(Bio-Rad Laboratories).
Confocal microscopy and live imaging. CD4+ T cells were purified
from SJL mouse using CD4 T cell enrichment column (R&D Systems) and
stained with Alexa Fluor 488–conjugated anti–mouse CD3 mAb (BioLegend).
Labeled cells were placed in a Live Imaging Microincubator (Carl Zeiss
MicroImaging, Inc.) at 37°C and 5% CO2 for monitoring cell responses to the
treatment with rIgG2a, 3B3, or RMT1-10 antibodies. Data were recorded
for 1 h with a LSM510 laser-scanning confocal microscope (Carl Zeiss
MicroImaging, Inc.) by using z-stack of the cultures to obtain the behavior
of the entire body of cells and not just a single optical plane over time;
these allow us to firmly establish the activity of both antibodies in CD3
capping and cell movement. Three-dimensional reconstructions were performed for every experiment and followed for the duration of the experiments, and the percentage of cells demonstrating capping and extended
short-range movement, increased motility were annotated. Laser scanning
parameters were maintained to a minimum to avoid any potential photodamage, and results were analyzed with LSM 510 software (Carl Zeiss
MicroImaging, Inc.) and processed using LSM 510 confocal software, as
previously described (24, 44).
Biacore analysis. A Biacore T100 system (Biacore, Inc.) was used for kinetic analysis of anti–Tim-1 antibodies 3B3 and RMT1-10 with a reaction
temperature of 37°C. Goat anti–rat IgG Fc was immobilized to the CM5
carboxymethylated dextran sensor chip. 5 nM of 3B3 or RMT1-10 was
injected over the chip surface for 3 min at 10 μl/min. The reference flow
cell was injected with rIgG2a. Tim-1-Ig, at concentrations of 5, 2.5, 1.25,
0.625, 0.3125, 0.156, and 0.078 nM, and buffer only was introduced to the
chip surface using a high-performance injection for 4 min at 30 μl/min. For
each concentration, dissociation of bound antigen in the buffer flow was
recorded for an additional 20 min. The sensor chip surface was regenerated with a 30-s injection of 20 mM HCl at 60 μl/min, followed by a 30-s
stabilization period.
For anti–Tim-1 epitope mapping, a Biacore 3000 system was used with
a reaction temperature of 25°C. 10 μg/ml of anti–Tim-1 antibody 3B3 were
injected over the goat anti–rat IgG Fc-immobilized chip surface for 1 min
at 10 μl/min. The chip surface was then saturated with rIgG. A mixture of
10 μg/ml Tim-1-Ig and 100 μg/ml anti–Tim-1 antibody (3B3, RMT1-10,
or control antibody) was injected over the chip surface for 3 min at 10 μl/
min. The sensor chip surface was regenerated with a 40-s injection of 20 mM
HCl at 60 μl/min.
Data transformation and sensogram plot overlays were prepared using
BIAevaluation software for Biacore 3000 data, and Biacore T100 evaluation
software was used for kinetic analysis of association and dissociation rates. All
sensogram data were subtracted from the reference flow cell and double referenced using buffer injection data from each condition tested. Association
and dissociation kinetics were determined using a bivalent analyte algorithm
with global fit analysis.
Statistics. Comparisons of the differences in biacore data or immune responses, such as proliferation and cytokine production and numbers of IAs
tetramer-positive CD4+ T cells, were made using Student’s t tests. The clinical score and incidence of PLP139-151-induced EAE was analyzed by Fisher’s
exact test. P < 0.05 was considered significant.
Online supplemental material. Fig. S1 shows the effects of Fab′ fragments of 3B3 and RMT1-10 on T cell proliferation and cytokine production. Video 1 shows that treatment with 3B3, but not RMT1-10,
anti–Tim-1 antibody causes highly motile T cells with changes in morphology. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20062498/DC1.
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ONLINE SUPPLEMENTAL MATERIAL

Xiao et al., http://www.jem.org/cgi/content/full/jem.20062498/DC1
Supplemental materials and methods
Proliferation assays and cytokine intracellular staining
Female SJL mice were immunized with PLP139-151/CFA. On day 10, spleen cells were isolated and plated in round-bottomed
96-well plates in culture medium with various concentrations of PLP139-151 plus 10 μg/ml of control Ab, Fab’ RMT1-10, or
Fab’ 3B3. Forty-eight hours later, plates were pulsed for 16 h with 1 μCi [3H]-thymidine per well. Proliferation was measured
as counts per minute (cpm) by using a Wallac liquid scintillation counter. Spleen cells were also cultured in 24-well plates with
PLP139-151 plus control mAb, 3B3, RMT1-10, or their Fab’ fragments for 6 d. Then, cells were purified by Ficoll-Hypaque
density gradient centrifugation and reactivated with PMA (20ng/ml) and ionomycin (300ng/ml) and 2mM monensin (GolgiStop, BD Biosciences) for 4 h at 37°C. After staining with APC-anti-CD4, and 7-AAD, the cells were fixed, permeabilized, and
stained with PE-cytokine Ab as recommended by the manufacturer (BD Biosciences). The frequencies of cytokine-producing
cells were then analyzed with the programs CELLQUEST and FlowJo by gating on CD4+7-AAD- populations.
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